文献速递前列腺癌

基线多参数磁共振成像上1级前列腺癌的可见性是否影响临床结局?

Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
PubMed 文献 · J Urol · 2020-06-04

该研究评估454例经磁共振靶向活检确诊为最高级别为1级前列腺癌的男性,基线多参数磁共振成像(mpMRI)分级为阴性、可疑或阳性。中位随访45.2个月,阳性mpMRI与更短的无治疗生存、更短的无活检升级生存及根治性前列腺切除术后不利病理风险增加相关。

要点

  • 基线mpMRI阳性与1级前列腺癌患者无治疗生存期缩短相关。
  • mpMRI阳性是无活检升级生存的显著预后因素。
  • mpMRI阳性者根治性前列腺切除术后不利病理风险增加。

核心结论

  • 在接受磁共振靶向活检确诊为最高1级前列腺癌的男性中,基线mpMRI阳性提示更高的干预、活检升级及根治性前列腺切除术后不利病理风险。

研究设计与样本

  • 研究纳入2006至2018年间接受mpMRI且经磁共振靶向活检确诊最高级别为1级前列腺癌的454例男性。
  • mpMRI分级为阴性、可疑或阳性,评估无治疗生存、无活检升级生存及根治性前列腺切除术后不利疾病。

主要发现

  • 中位随访45.2个月期间,61例随访活检升级,139例接受确定性治疗。
  • 基线mpMRI阴性、可疑、阳性组5年无治疗生存率分别为79%、73%、49%(p <0.0001)。
  • 三组5年无活检升级生存率分别为89%、82%、70%(p=0.002)。
  • 三组5年无根治性前列腺切除术后不利疾病生存率分别为98%、98%、86%(p=0.007)。

关键数值与推荐

  • 多变量分析中,阳性mpMRI与更短无治疗生存相关(HR 1.93,95% CI 1.21-3.09,p=0.006)。
  • 可疑mpMRI亦与更短无治疗生存相关(HR 2.02,95% CI 1.11-3.68,p=0.02)。
  • 阳性mpMRI是无活检升级生存的显著预后因素(HR 2.03,95% CI 1.06-3.86,p=0.03)。
  • 阳性mpMRI是根治性前列腺切除术后不利疾病的显著预后因素(HR 4.45,95% CI 1.39-18.17,p=0.01)。

临床怎么用

  • 对于磁共振靶向活检确诊为1级前列腺癌且基线mpMRI阳性的患者,应考虑更密切随访或积极干预咨询。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed whether the visibility of Grade Group (GG) 1 prostate cancer on baseline multiparametric magnetic resonance imaging affects clinical outcomes. MATERIALS AND METHODS: We evaluated 454 men who underwent multiparametric magnetic resonance imaging between 2006 and 2018 with maximum GG1 prostate cancer inclusive of magnetic resonance imaging targeted biopsy. Multiparametric magnetic resonance imaging was graded as negative, equivocal or positive. Assessed outcomes were treatment-free survival, biopsy upgrade-free survival and unfavorable disease at radical prostatectomy (pT 3 or greater and/or GG3 or greater). Kaplan-Meier and multivariable Cox proportional hazard analyses were used to estimate the impact of multiparametric magnetic resonance imaging and clinicopathological variables (age, year, prostate specific antigen density and measures of tumor volume on biopsy) on outcomes. RESULTS: During followup (median 45.2 months) 61 men had disease upgraded on followup biopsy and 139 underwent definitive treatment. In men with negative, equivocal and positive baseline multiparametric magnetic resonance imaging at 5 years, treatment-free survival was 79%, 73% and 49% (p <0.0001), treatment-free survival was 89%, 82% and 70% (p=0.002), and survival without unfavorable disease at radical prostatectomy was 98%, 98% and 86% (p=0.007), respectively. At multivariable analysis positive (HR 1.93, 95% CI 1.21-3.09, p=0.006) and equivocal multiparametric magnetic resonance imaging (HR 2.02, 95% CI 1.11-3.68, p=0.02) were associated with shorter treatment-free survival, and positive multiparametric magnetic resonance imaging was a significant prognostic factor for upgrade-free survival (HR 2.03, 95% CI 1.06-3.86, p=0.03) and unfavorable disease at radical prostatectomy (HR 4.45, 95% CI 1.39-18.17, p=0.01). CONCLUSIONS: Men with positive multiparametric magnetic resonance imaging and GG1 prostate cancer on magnetic resonance imaging targeted biopsy are at increased risk for intervention, upgrading and unfavorable disease at radical prostatectomy compared to those with multiparametric magnetic resonance imaging invisible GG1 prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Deniffel D, Salinas E, Ientilucci M, et al. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes? J Urol. 2020. PMID: 32496160. doi:10.1097/JU.0000000000001157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。